Tamoxifen Ebewe is an immunomodulatory and antineoplastic drug. It is used in hormonal therapy of oncological neoplasms. Belongs to the group of androgenic drugs. Tamoxifen Ebewe is produced in Austria.
Composition
The content of this pharmacological product contains the main active element - tamoxifen citrate (40, 30, 20 or 10 mg per tablet). It is produced in contour cells of 10 tablets, placed in cartons of 10 pieces.
1 tablet contains:
- tamoxifen citrate;
- lactose;
- magnesium stearate;
- starch;
- cellulose;
- colloidal silicon dioxide.
Pills are round, white, with a cross-shaped dividing groove on one side.
Pharmacological properties
The active ingredient amoxifen is an antiestrogen non-steroidal substance that also has a weak estrogenic property. Hisantitumor effect is based on the ability to block estrogen receptors.
Tamoxifen and its metabolites compete with estradiol instead of binding to cytoplasmic estrogen receptors in breast, vaginal, uterine, anterior pituitary, and neoplasms with a high concentration of estrogen receptors. Tamoxifen does not stimulate the production of DNA in the nucleus, but inhibits cell division, which contributes to the regression of pathological cells and their destruction.
Pharmacokinetics
After taking tamoxifen is well absorbed. The highest concentration in the blood occurs approximately 4-7 hours after a single dose. The equilibrium level of this active element in the serum, as a rule, is reached after 3 weeks of use. It goes through the process of metabolism in the liver with the formation of several substances. Excretion from the body has a two-stage nature with an initial half-life of 7 to 13 hours, followed by a terminal half-life of 7 days. This substance is excreted mainly in the form of conjugates, with feces and in small amounts with urine.
Medical indications for the use of this drug
This medicine is mainly used for early signs of breast cancer. Typical symptoms of this pathology are:
- formation in the gland seals inchest;
- retraction or thickening of the nipple;
- appearance of a "lemon peel" over the pathological focus;
- redness of the skin;
- consolidation of axillary and retrosternal lymph nodes;
- disproportionate increase in size of one breast;
- appearance of pain syndrome;
- breast deformity;
- puffiness;
- crusting, ulceration;
- presence of discharge from the nipple (including bloody);
- temperature increase;
- general weakness;
- drastic weight loss;
- dizziness.
In addition, the drug "Tamoxifen-Ebewe" is prescribed for the following pathologies:
- estrogen-dependent breast cancer in men;
- ovarian, endometrial, kidney cancer;
- melanoma;
- soft tissue sarcoma with estrogen receptor tumors;
- prostate cancer with resistance to other drugs.
Contraindications for the use of this medication
Tamoxifen-Ebewe is contraindicated in the following cases:
- sensitivity to tamoxifen or other ingredient of the product;
- lactation, pregnancy.
With caution, this drug is prescribed for kidney failure, diabetes mellitus, eye diseases (cataracts), deep vein thrombosis and thromboembolic disease (including history), hyperlipidemia, leukopenia, thrombocytopenia, hypercalcemia.
ModeDosing and how to take this drug
To achieve the best effect on early signs of breast cancer, the recommended regimen for this medication is 20 to 40 mg orally daily in a long course. If symptoms of the progression of the pathological process appear, the drug is canceled.
Pills do not require chewing, washed down with a small amount of water, once in the morning or divided into two doses.
Side effects of "Tamoxifen Ebewe"
During tamoxifen therapy, side effects associated with its antiestrogenic effects are common, which manifest themselves as paroxysmal feelings of heat (hot flashes), vaginal discharge or bleeding, itching in the genital area, alopecia, soreness in the lesion area, weight gain body, ossalgia. The following adverse reactions are somewhat less common:
- fluid retention;
- nausea;
- anorexia;
- vomit;
- stool disorders;
- fatigue;
- depressive states;
- confusion;
- cephalgia;
- dizziness;
- increased sleepiness;
- hyperthermia;
- skin rash;
- violation of visual function;
- retinopathy;
- retrobulbar neuritis.
At the beginning of therapy, there may be a local exacerbation of the disease - an increase in the size of soft tissue neoplasms, whichsometimes accompanied by severe episodes of erythema in the affected areas and adjacent areas - which in most cases resolves within 14 days.
The likelihood of developing thromboembolism and thrombophlebitis may also increase. Occasionally, transient thrombocytopenia and leukopenia may occur, as well as an increase in liver enzymes, in rare cases accompanied by severe liver dysfunction, such as fatty infiltration, hepatitis and cholestasis.
Some patients with bone metastases have experienced symptoms of hypercalcemia at the start of therapy. Tamoxifen may contribute to amenorrhea or cause menstrual irregularity in the pre-menopausal period, as well as reversible formation of cystic formations on the ovaries.
With prolonged treatment with this medicinal product, endometrial changes such as hyperplasia, polyps and, in rare cases, endometrial cancer, uterine fibroma, may also occur.
Reviews about "Tamoxifen Ebewe"
There are very few reviews of such a medicine on medical websites, and this is due to the fact that oncological diseases do not occur in people too often, especially since such medicines are not always prescribed for them.
From the information on a few reviews, we can conclude that Tamoxifen-Ebewe was not always effective, but only in about half of the cases of its use. Patients indicate a good tolerability of this treatment. In many of them, the growth of a pathological neoplasm during therapywas suspended, others did not have this effect, and these people were prescribed other treatment.
